Correction to: Pharm Res (2017) 34:2749–2755
https://doi.org/ 10.1007/s11095-017-2255-7
There are errors in the published article (Volume 34, Number 12, pp. 2749–2755).
The errors occurred in pharmacokinetic study design of materials and methods section on page 2750–51.
1. Another group of 15 mice (3 mice/time point) were injected SubQ with 200 mg/kg (each TAF, FTC, and EVG) of free drug in 1 mL of 5% dextrose.
FTC is not related to the objective of this article and it has no reported drug-drug interactions that could affect PK of TAF and EVG [1].
Refererence
1. AIDSinfo, Drug interactions between nucleoside reverse transcriptase inhibitors and other drugs (including antiretroviral agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & human Services, Washington, DC, USA, 2018.
2. Institutional animal care and use committee approved protocol (#0989) and procedures were followed. However, the authors retrospectively found that “injecting naïve TAF+FTC+EVG solution to mice” was not in the approved protocol.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s11095-017-2255-7
Rights and permissions
About this article
Cite this article
Prathipati, P.K., Mandal, S., Pon, G. et al. Correction to: Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model. Pharm Res 36, 108 (2019). https://doi.org/10.1007/s11095-019-2638-z
Published:
DOI: https://doi.org/10.1007/s11095-019-2638-z